N E W S B Y T E S
products listed in the National List of Essential Medicines ( NLEM ).
Exports for the quarter grew by 30 % as compared to Q2 2022 . The Company was largely able to maintain its gross margins , despite the NLEM impact . The Profit from Operations for the quarter were at INR 168 crores versus INR 150 crores in the previous year , i . e ., a growth of 12 % while the operating margins increased from 21.5 % in Q2 2022 to 23.7 % in Q2 2023 . The improved operating margins were a result of the Company ’ s focus mainly on lowering expenses through overall operating efficiencies .
CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests
CrisprBits , a biotech start-up specializing in CRISPR gene-editing technology , has announced a strategic collaboration with Molbio Diagnostics , a pioneer in point of care diagnostic solutions . The intent of this collaboration is to revolutionize point of care diagnostics by the introduction of CRISPR in Point-of-Care ( POC ) tests .
The strategic partnership between CrisprBits and Molbio Diagnostics represents a significant milestone in the advancement of accessible , cost effective and accurate diagnostic testing in the frontline . The collaboration is set to identify and capitalize on market opportunities , bringing together their respective strengths and expertise . By harnessing the unprecedented sensitivity and specificity of RNA guide-based target identification of nucleic acid , and the presence of both cis and trans-cleavage property of certain Cas enzymes , CrisprBits has developed a platform to build rapid , precise , and affordable POC tests for a wide range of disease and health conditions .
40
BioVoiceNews | September 2023